|
To listen to individual tracks now, click the  icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or  MP3 for users with other audio players.
|
| Track 1 |
Introduction by Neil Love, MD |
|
|
| Track 2 |
Phase II trial of capecitabine combined with weekly paclitaxel for metastatic breast cancer |
|
|
| Track 3 |
Tolerability and efficacy of paclitaxel/capecitabine versus docetaxel/capecitabine |
|
|
| Track 4 |
Collateral sensitivity to anthracyclines, taxanes and antimetabolites |
|
|
| Track 5 |
Importance of tumor biology in determining drug sensitivity |
|
|
| Track 6 |
Defining subsets of breast cancer based on similarity of gene expression |
|
|
| Track 7 |
Identification and potential treatment of basal-like breast cancer |
|
|
| Track 8 |
Ongoing trials evaluating capecitabine-containing regimens in the adjuvant setting |
|
|
| Track 9 |
Rationale for sequential use of chemotherapy and tamoxifen |
|
|
| Track 10 |
Differences in recurrence patterns between ER-positive and ER-negative breast cancer |
|
|
| Track 11 |
US Oncology neoadjuvant trial with FEC 100 followed by weekly docetaxel/capecitabine |
|
|
| Track 12 |
Nonprotocol use of neoadjuvant and adjuvant trastuzumab |
|
|
| Track 13 |
Rationale for synergy between trastuzumab and anthracyclines |
|
|
| Track 14 |
Management of ER-positive, HER2-positive metastatic disease |
|
|
| Track 15 |
Trastuzumab monotherapy versus trastuzumab in combination with chemotherapy |
|
|
| Track 16 |
Developing treatment approaches based on observed clinical patterns |
|
|
| |
|
|
|
| |
|
|
|
 |
Charles E Geyer Jr, MD
Director of Medical Affairs
National Surgical Adjuvant Breast and Bowel Project
Director of Breast Medical Oncology
Allegheny General Hospital
Pittsburgh, Pennsylvania
Click here to download the entire interview |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Cardiac toxicity observed in NSABP-B-31 |
|
|
| Track 3 |
Potential strategies to limit cardiotoxicity from trastuzumab and chemotherapy |
|
|
| Track 4 |
Perspectives on the MD Anderson neoadjuvant trastuzumab data |
|
|
| Track 5 |
Nonprotocol use of adjuvant trastuzumab |
|
|
| Track 6 |
Lack of survival benefit observed in NSABP-B-27 |
|
|
| Track 7 |
Pathologic complete response as a surrogate for long-term outcome |
|
|
| Track 8 |
Rationale for inclusion of gemcitabine in NSABP-B-38 |
|
|
| Track 9 |
NSABP-B-40: Neoadjuvant trial of AC followed by docetaxel versus docetaxel/capecitabine versus docetaxel/gemcitabine |
|
|
| Track 10 |
NSABP-B-35: Anastrozole versus tamoxifen for DCIS |
|
|
| Track 11 |
NSABP study using Oncotype DX™ assay to predict benefit from chemotherapy |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Switching from one hormonal therapy to another to overcome drug resistance |
|
|
| Track 3 |
Austrian-German trial of switching to anastrozole after two years of adjuvant tamoxifen |
|
|
| Track 4 |
Perspectives on 68-month follow-up from the ATAC trial |
|
|
| Track 5 |
Nonprotocol selection of first-line hormonal therapy for postmenopausal women
with ER-positive disease |
|
|
| Track 6 |
ABCSG-12: Goserelin/tamoxifen versus goserelin/anastrozole with or without zoledronic acid |
|
|
| Track 7 |
Switching patients from tamoxifen to an aromatase inhibitor in the nonprotocol setting |
|
|
| Track 8 |
Poor prognosis of premenopausal patients with ER-positive, HER2-positive disease |
|
|
| Track 9 |
Benefit of six versus three cycles of neoadjuvant epirubicin/docetaxel |
|
|
| Track 10 |
HERA trial of adjuvant trastuzumab |
|
|
| Track 11 |
Nonprotocol management of premenopausal patients with ER-positive tumors |
|
|
| Track 12 |
Differences in the effect of chemotherapy for ER-positive and ER-negative disease |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Oncotype DX assay to predict benefit from tamoxifen in ER-positive, node-negative disease |
|
|
| Track 3 |
NSABP study to assess ability of Oncotype DX assay to predict response to chemotherapy |
|
|
| Track 4 |
Impact of NSABP Oncotype DX data on clinical trial design and patient management |
|
|
| Track 5 |
Lack of benefit from tamoxifen in patients with high recurrence scores based on Oncotype DX assay |
|
|
| Track 6 |
Applicability of Oncotype DX assay for patients treated with aromatase inhibitors |
|
|
| Track 7 |
Predictors of response to specific chemotherapeutic regimens |
|
|
| Track 8 |
Predictors of response to trastuzumab |
|
|
| Track 9 |
Correlation between HER2 status and response to tamoxifen |
|
|
| Track 10 |
Clinical algorithm for employing the Oncotype DX assay in practice |
|
|
| Track 11 |
Comprehensive survey of amplified genes in breast cancer |
|
|
| Track 12 |
Importance of tissue banking for the future of cancer research |
|
|
|
|
